- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07795164
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (PERFORMA)
A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Shaheen Tomah, MD
- Phone Number: 240-235-0145
- Email: performa@altimmune.com
Study Locations
-
-
Puerto Rico
-
San Juan, Puerto Rico, Puerto Rico, 00927
- Recruiting
- Altimmune Clinical Study Site
-
-
-
-
Alabama
-
Dothan, Alabama, United States, 36301
- Recruiting
- Altimmune Clinical Study Site
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Recruiting
- Altimmune Clinical Study Site
-
Tucson, Arizona, United States, 85712
- Recruiting
- Altimmune Clinical Study Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- Altimmune Clinical Study Site
-
North Little Rock, Arkansas, United States, 72117
- Recruiting
- Altimmune Clinical Study Site
-
-
California
-
Fountain Valley, California, United States, 92708
- Recruiting
- Altimmune Clinical Study Site
-
Fresno, California, United States, 93720
- Recruiting
- Altimmune Clinical Study Site
-
Gardena, California, United States, 90247
- Recruiting
- Altimmune Clinical Study Site
-
Huntington Park, California, United States, 90255
- Recruiting
- Altimmune Clinical Study Site
-
La Mesa, California, United States, 91942
- Recruiting
- Altimmune Clinical Study Site
-
Long Beach, California, United States, 90815
- Recruiting
- Altimmune Clinical Study Site
-
Orange, California, United States, 92866
- Recruiting
- Altimmune Clinical Study Site
-
Orange, California, United States, 92868
- Recruiting
- Altimmune Clinical Study Site
-
Poway, California, United States, 92064
- Recruiting
- Altimmune Clinical Study Site
-
Van Nuys, California, United States, 91405
- Recruiting
- Altimmune Clinical Study Site
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- Recruiting
- Altimmune Clinical Study Site
-
-
Florida
-
Boca Raton, Florida, United States, 33434
- Recruiting
- Altimmune Clinical Study Site
-
Bradenton, Florida, United States, 34209
- Recruiting
- Altimmune Clinical Study Site
-
Miami, Florida, United States, 33173
- Recruiting
- Altimmune Clinical Study Site
-
Miami, Florida, United States, 33122
- Recruiting
- Altimmune Clinical Study Site
-
Miami Lakes, Florida, United States, 33016
- Recruiting
- Altimmune Clinical Study Site
-
Ocala, Florida, United States, 34471
- Recruiting
- Altimmune Clinical Study Site
-
Orlando, Florida, United States, 32803
- Recruiting
- Altimmune Clinical Study Site
-
Port Orange, Florida, United States, 32127
- Recruiting
- Altimmune Clinical Study Site
-
-
Georgia
-
Dalton, Georgia, United States, 30720
- Recruiting
- Altimmune Clinical Study Site
-
-
Indiana
-
South Bend, Indiana, United States, 46635
- Recruiting
- Altimmune Clinical Study Site
-
-
Louisiana
-
Bastrop, Louisiana, United States, 71220
- Recruiting
- Altimmune Clinical Study Site
-
Marrero, Louisiana, United States, 70072
- Recruiting
- Altimmune Clinical Study Site
-
Monroe, Louisiana, United States, 71201
- Recruiting
- Altimmune Clinical Study Site
-
-
Maryland
-
Laurel, Maryland, United States, 20708
- Recruiting
- Altimmune Clinical Study Site
-
-
Massachusetts
-
New Bedford, Massachusetts, United States, 02740
- Recruiting
- Altimmune Clinical Study Site
-
-
Missouri
-
Columbia, Missouri, United States, 65201
- Recruiting
- Altimmune Clinical Study Site
-
Kansas City, Missouri, United States, 64131
- Recruiting
- Altimmune Clinical Study Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87107
- Recruiting
- Altimmune Clinical Study Site
-
-
North Carolina
-
Fayetteville, North Carolina, United States, 28304
- Recruiting
- Altimmune Clinical Study Site
-
-
Ohio
-
Brooklyn, Ohio, United States, 44144
- Recruiting
- Altimmune Clinical Study Site
-
Springboro, Ohio, United States, 45066
- Recruiting
- Altimmune Clinical Study Site
-
Westlake, Ohio, United States, 44145
- Recruiting
- Altimmune Clinical Study Site
-
-
Rhode Island
-
East Greenwich, Rhode Island, United States, 02818
- Recruiting
- Altimmune Clinical Study Site
-
-
Texas
-
Austin, Texas, United States, 78757
- Recruiting
- Altimmune Clinical Study Site
-
Bellaire, Texas, United States, 77401
- Recruiting
- Altimmune Clinical Study Site
-
Brownsville, Texas, United States, 78520
- Recruiting
- Altimmune Clinical Study Site
-
Corpus Christi, Texas, United States, 78404
- Recruiting
- Altimmune Clinical Study Site
-
Dallas, Texas, United States, 75230
- Recruiting
- Altimmune Clinical Study Site
-
Edinburg, Texas, United States, 78539
- Recruiting
- Altimmune Clinical Study Site
-
Farmers Branch, Texas, United States, 75234
- Recruiting
- Altimmune Clinical Study Site
-
Forney, Texas, United States, 75126
- Recruiting
- Altimmune Clinical Study Site
-
Fort Worth, Texas, United States, 76104
- Recruiting
- Altimmune Clinical Study Site
-
Georgetown, Texas, United States, 78626
- Recruiting
- Altimmune Clinical Study Site
-
Houston, Texas, United States, 77004
- Recruiting
- Altimmune Clinical Study Site
-
Houston, Texas, United States, 77079
- Recruiting
- Altimmune Clinical Study Site
-
Kingwood, Texas, United States, 77339
- Recruiting
- Altimmune Clinical Study Site
-
Pasadena, Texas, United States, 77505
- Recruiting
- Altimmune Clinical Study Site
-
San Antonio, Texas, United States, 78215
- Recruiting
- Altimmune Clinical Study Site
-
San Antonio, Texas, United States, 78209
- Recruiting
- Altimmune Clinical Study Site
-
San Antonio, Texas, United States, 78229
- Recruiting
- Altimmune Clinical Study Site
-
Sugar Land, Texas, United States, 77479
- Recruiting
- Altimmune Clinical Study Site
-
Waco, Texas, United States, 76710
- Recruiting
- Altimmune Clinical Study Site
-
-
Utah
-
Ogden, Utah, United States, 84405
- Recruiting
- Altimmune Clinical Study Site
-
West Jordan, Utah, United States, 84088
- Recruiting
- Altimmune Clinical Study Site
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Altimmune Clinical Study Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All subjects:
- No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
- Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
- Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
- Subject agrees to have liver biopsy(ies) as required per protocol
Cohort 1 - Histologic diagnosis of F2/F3 MASH based on liver biopsy during screening or historical biopsy within 6 months before screening
Cohort 2 - Presumed F2/F3 MASH based on noninvasive testing
Exclusion Criteria:
- Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
- Uncontrolled T2D or clinically significant persistent hyperglycemia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo SC Injection |
|
Experimental: Pemvidutide 2.4 mg
|
Pemvidutide SC Injection |
|
Experimental: Pemvidutide 1.8 mg
|
Pemvidutide SC Injection |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Outcome Event
Time Frame: Baseline through end of study (approximately Month 60)
|
Time to first occurrence of any of the following events through the end of the study: Histologic progression to cirrhosis (F4) on liver biopsy; Liver related events; Liver transplantation; or Death due to any cause |
Baseline through end of study (approximately Month 60)
|
|
Histological Response: MASH resolution
Time Frame: Baseline through Week 52
|
Proportion of subjects achieving MASH resolution (according to NASH Clinical Research Network [CRN] classification) without worsening of fibrosis |
Baseline through Week 52
|
|
Histological Response: Fibrosis improvement
Time Frame: Baseline through Week 52
|
Proportion of subjects achieving ≥ 1 stage improvement in liver fibrosis according to the NASH CRN fibrosis staging system without worsening of MASH |
Baseline through Week 52
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASH
Time Frame: Baseline through Week 52
|
Baseline through Week 52
|
|
HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosis
Time Frame: Baseline through Week 52
|
Baseline through Week 52
|
|
Anthropometric parameters: Relative (%) change from baseline in body weight (kg)
Time Frame: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2)
Time Frame: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm)
Time Frame: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L)
Time Frame: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) score
Time Frame: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by Fibroscan
Time Frame: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire.
Time Frame: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores.
Time Frame: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores.
Time Frame: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ALT-801-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.